Eszol Contraindications

Eszol is contra-indicated in patients with known hypersensitivity to itraconazole or to any of the excipients.
Coadministration of the following drugs is contraindicated with Eszol: CYP3A4 metabolised substrates that can prolong the QT-interval e.g., astemizole, bepridil, cisapride, dofetilide, levacetylmethadol (levomethadyl), mizolastine, pimozide, quinidine, sertindole and terfenadine are contraindicated with Eszol. Coadministration may result in increased plasma concentrations of these substrates which can lead to QTc prolongation and rare occurrences of torsades de pointes; CYP3A4 metabolised HMG-CoA reductase inhibitors such as atorvastatin, lovastatin and simvastatin; Triazolam and oral midazolam; Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine); Eletriptan; Nisoldipine; Eszol should not be administered for non-life threatening indications to patients receiving disopyramide or halofantrine.
Eszol should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections. See Precautions. Eszol must not be used during pregnancy for non-life-threatening indications (see Use in Pregnancy & Lactation).
Women of childbearing potential taking Eszol should use contraceptive precautions. Effective contraception should be continued until the menstrual period following the end of Eszol therapy.